← All trials
NCT03789552
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 28, 2019
- Primary completion
- Apr 1, 2022
- Completion date
- Sep 1, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 765
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tasly Pharmaceuticals, Inc.Lead sponsor
- Tasly Pharmaceuticals, Inc.Study chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.